JAM3, junctional adhesion molecule 3, 83700

N. diseases: 66; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.010 Biomarker disease BEFREE Restoration of JAM3 repressed CRC cell viability, colony formation, and migration. 30988641 2019
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.010 PosttranslationalModification disease BEFREE JAM3 functions as a novel tumor suppressor and is inactivated by DNA methylation in colorectal cancer. 30988641 2019
CUI: C0001175
Disease: Acquired Immunodeficiency Syndrome
Acquired Immunodeficiency Syndrome 		0.010 Biomarker group BEFREE Junctional adhesion molecule C (JAM-C) dimerization aids cancer cell migration and metastasis. 29378216 2018
CUI: C0007134
Disease: Renal Cell Carcinoma
Renal Cell Carcinoma 		0.010 Biomarker disease BEFREE The role of Jam3 in the migration and apoptosis of renal carcinoma cells was determined using small interfering RNA, wound‑healing assays, flow cytometry, and cell migration assays. 30226554 2018
CUI: C0007847
Disease: Malignant tumor of cervix
Malignant tumor of cervix 		0.010 Biomarker disease BEFREE The key findings of the study demonstrated that miR-374b significantly inhibits cell proliferation, migration, and invasion through the blockade of the p38/ERK signaling pathway activation, as well as negatively binding to JAM-2, highlighting its potential as a therapeutic target for CC. 29575013 2018
CUI: C0008312
Disease: Primary biliary cirrhosis
Primary biliary cirrhosis 		0.010 AlteredExpression disease BEFREE Here, we demonstrate that biopsies of patients suffering from primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) or autoimmune hepatitis (AIH) display elevated levels of JAM-C on portal fibroblasts (PFs), HSCs, endothelial cells and cholangiocytes, whereas smooth muscle cells expressed JAM-C constitutively. 29753567 2018
CUI: C0019158
Disease: Hepatitis
Hepatitis 		0.010 Biomarker group BEFREE Therefore, localization and function of JAM-B and JAM-C were investigated in three mouse models of autoimmune-driven liver inflammation. 29753567 2018
CUI: C0036690
Disease: Septicemia
Septicemia 		0.010 AlteredExpression disease BEFREE Soluble JAM-C level in serum was up-regulated during sepsis. 30088666 2018
CUI: C0235982
Disease: Stricture of bile duct
Stricture of bile duct 		0.010 Biomarker disease BEFREE This might be different in patients and may even be complicated by the fact that human leukocytes express JAM-C. Our findings delineate JAM-C as a mediator of myofibroblast-operated contraction of the liver capsule, intrahepatic vasoconstriction and bile duct stricture. 29753567 2018
CUI: C0238478
Disease: Transient erythroblastopenia of childhood
Transient erythroblastopenia of childhood 		0.010 AlteredExpression disease BEFREE Moreover, upregulation of RhoT1 level by decreased the degradation of RhoT1 could decrease the expression of SMAD-4 and increase the JAM-3 level in TECs treated with LPS, while downregulation of RhoT1 level with RNA interference had the opposite effects. 29725250 2018
CUI: C0239946
Disease: Fibrosis, Liver
Fibrosis, Liver 		0.010 Biomarker disease BEFREE Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice. 29753567 2018
CUI: C0241910
Disease: Autoimmune Chronic Hepatitis
Autoimmune Chronic Hepatitis 		0.010 AlteredExpression disease BEFREE Here, we demonstrate that biopsies of patients suffering from primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) or autoimmune hepatitis (AIH) display elevated levels of JAM-C on portal fibroblasts (PFs), HSCs, endothelial cells and cholangiocytes, whereas smooth muscle cells expressed JAM-C constitutively. 29753567 2018
CUI: C0243026
Disease: Sepsis
Sepsis 		0.010 AlteredExpression disease BEFREE Soluble JAM-C level in serum was up-regulated during sepsis. 30088666 2018
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma 		0.010 Biomarker disease BEFREE The key findings of the study demonstrated that miR-374b significantly inhibits cell proliferation, migration, and invasion through the blockade of the p38/ERK signaling pathway activation, as well as negatively binding to JAM-2, highlighting its potential as a therapeutic target for CC. 29575013 2018
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis 		0.010 Biomarker disease BEFREE Analysis of a murine model of PSC revealed a role of JAM-C in PF cell-cell adhesion and contractility. 29753567 2018
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.010 GeneticVariation disease BEFREE Leukemogenesis is almost completely abrogated upon Jam3 deletion during serial transplantations in an MLL-AF9-induced murine acute myeloid leukemia model. 29584620 2018
CUI: C1378703
Disease: Renal carcinoma
Renal carcinoma 		0.010 Biomarker disease BEFREE The role of Jam3 in the migration and apoptosis of renal carcinoma cells was determined using small interfering RNA, wound‑healing assays, flow cytometry, and cell migration assays. 30226554 2018
CUI: C4048328
Disease: cervical cancer
cervical cancer 		0.010 Biomarker disease BEFREE The key findings of the study demonstrated that miR-374b significantly inhibits cell proliferation, migration, and invasion through the blockade of the p38/ERK signaling pathway activation, as well as negatively binding to JAM-2, highlighting its potential as a therapeutic target for CC. 29575013 2018
CUI: C4721555
Disease: Autoimmune hepatitis
Autoimmune hepatitis 		0.010 AlteredExpression disease BEFREE Here, we demonstrate that biopsies of patients suffering from primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) or autoimmune hepatitis (AIH) display elevated levels of JAM-C on portal fibroblasts (PFs), HSCs, endothelial cells and cholangiocytes, whereas smooth muscle cells expressed JAM-C constitutively. 29753567 2018
CUI: C0022660
Disease: Kidney Failure, Acute
Kidney Failure, Acute 		0.010 Biomarker disease BEFREE Blocking junctional adhesion molecule C promotes the recovery of cisplatin-induced acute kidney injury. 28192890 2017
CUI: C0023418
Disease: leukemia
leukemia 		0.010 Biomarker disease BEFREE JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. 28972073 2017
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.010 Biomarker disease BEFREE JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. 28972073 2017
CUI: C0028960
Disease: Oligospermia
Oligospermia 		0.010 GeneticVariation disease BEFREE A significant association was identified between RPS6KA2 hypermethylation and advanced age (P = 0.016); APCS hypermethylation and oligozoospermia (P = 0.041); JAM3/NCAPD3 hypermethylation and numerical chromosome sperm anomalies (P = 0.048); and ANK2 hypermethylation and lower pregnancy rate (P = 0.040). 27692602 2016
CUI: C2677180
Disease: Congenital microcephaly
Congenital microcephaly 		0.010 GeneticVariation disease BEFREE Endothelial adhesion disruptions due to mutations in OCLN or JAM3 also cause congenital microcephaly, intracranial calcifications, and profound psychomotor disability. 27164683 2016
CUI: C0035309
Disease: Retinal Diseases
Retinal Diseases 		0.010 Biomarker group BEFREE Thus, targeting endothelial JAM-C may provide a novel therapeutic strategy for promoting revascularisation and vessel normalisation in the treatment of proliferative retinopathies. 26311310 2015